The aim of the study was to describe a case of type II diabetic peripheral small fiber neuropathic pain treated with whole body vibration therapy after a failed trial of conventional drugs and interventional pain management. A 64-year-old male had chronic diabetic peripheral neuropathic pain in his both feet for about 2 years. The patient tried multiple pain medications and various interventional pain treatments without significant pain relief. After 4 weeks of vibration treatment, which targeted the feet the patient's pain level and gait patterns significantly improved. These findings illustrate the importance of considering whole body vibration as a complimentary treatment in patients with diabetic peripheral neuropathic pain.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jbmt.2012.08.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
High HOMA2-B: A novel risk factor for diabetic peripheral neuropathy beyond metabolic syndrome components in type 2 diabetes.
J Diabetes Investig
January 2025
Laboratory of Medicine, Aichi Gakuin University School of Pharmacy, Nagoya, Aichi, Japan.
Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD.
J Hepatol
January 2025
Division of Endocrinology, Diabetes and Metabolism, University of Florida, Gainesville, Florida, United States of America. Electronic address:
Background & Aims: Lanifibranor is a pan-PPAR agonist that improves glucose/lipid metabolism and reverses steatohepatitis and fibrosis in adults with MASH. We tested its effect on insulin resistance at the level of different target tissues in relationship to change in intrahepatic triglyceride (IHTG) content.
Methods: This phase 2, single center, study randomized (1:1) 38 patients with T2D and MASLD to receive lanifibranor 800 mg or placebo for 24 weeks.
Comparing demographic/clinical characteristics, health care resource utilization, and costs among patients with type 2 diabetes and established atherosclerotic cardiovascular disease with and without the use of cardioprotective medications.
J Manag Care Spec Pharm
January 2025
Joslin Diabetes Center, Sequel Med Tech, Boston, MA.
Background: Type 2 diabetes (T2D) causes increased health care resource utilization (HCRU) and costs in the United States. People with T2D are more likely to have atherosclerotic cardiovascular disease (ASCVD), which is associated with significant morbidity and mortality. Medical associations recommend cardioprotective antidiabetic medications, including sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs), to reduce the risk of cardiovascular events in patients with T2D with established, or a high risk of, ASCVD, but not all eligible patients receive these medications.
View Article and Find Full Text PDFManifestations of human atherosclerosis across vascular beds.
JVS Vasc Insights
May 2024
Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University.
Objective: Atherosclerosis underlies the most common etiologies of mortality worldwide, resulting in nearly 10 million deaths annually. In atherosclerosis, inflammation, metabolic factors, and hemodynamics cause the accumulation of extracellular lipids and the formation of plaques in the tunica intima of specific arteries. Atherosclerotic plaques primarily form in the coronary and carotid arteries, the aorta, and the peripheral arteries of the lower extremities.
View Article and Find Full Text PDFEstimating Recent US Limb Loss Prevalence and Updating Future Projections.
Arch Rehabil Res Clin Transl
December 2024
Department of Orthopaedic Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Objective: To estimate limb loss prevalence in the United States (US) by etiology and anatomical position and the trends of limb loss over 40 years.
Design: We used the National Inpatient Sample, Healthcare Cost and Utilization Project to estimate current and future limb loss prevalence in the US and by anatomical location. Prevalence estimates were based on the incidence and duration of the disease.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!